IRCT20220209053979N10尚未招募Unknown
Bioequivalence Study of Carvedilol 12.5 mg tablet manufactured by Shafa Pharmaceutical and Coreg manufactured by GSK in 24 Healthy Volunteers under fed condition
Shafa Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Healthy male or female volunteers
- •Body mass index (BMI) between 18 - 30
- •Volunteers who are willing to sign an informed consent form
排除标准
- •Familial history of heart disease
- •History of allergy to Carvedilol or formulation components
- •History or significant clinical evidence of any disease
- •Taking any type of medicine in the 14 days before the start of the study
- •Participation in any clinical study within 30 days prior to study initiation
- •Systolic blood pressure less than 11 and diastolic less than 7 mmHg
研究者
相似试验
已完成
1 期
Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fed ConditionsHealthyNCT01064180Dr. Reddy's Laboratories Limited24
已完成
1 期
Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting ConditionsHealthyNCT01064154Dr. Reddy's Laboratories Limited36
已完成
1 期
Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mgHealthyNCT00648622Mylan Pharmaceuticals Inc50
已完成
1 期
Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mgHealthyNCT00650416Mylan Pharmaceuticals Inc50
招募中
3 期
Evaluation of the effect of carvedilol in patients with gastrointestinal cancerGastrointestinal cancers (Esophageal cancer, Gastric cancer, Pancreatic cancer, Colon cancer).Malignant neoplasm of stomachIRCT20200907048646N1Ardabil University of Medical Sciences60